Evidence map›Paper›PMID 39166278›Full record

Trial reportTechnology in cancer research & treatment

EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.

Fei Ye, Xiao Yuan, Wanjun Yu, Yali Ma, Chaoming Mao, Xiaoqin Li, Jian Li, Chunhua Dai, Fenhong Qian, Junrong Li and 7 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fei YeDepartment of Pharmacy, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Xiao YuanInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Wanjun YuDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
Yali MaDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
Chaoming MaoDepartment of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xiaoqin LiInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Jian LiDepartment of Respiratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Chunhua DaiInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Fenhong QianDepartment of Respiratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Junrong LiDepartment of Epidemiology and Biostatistics, School of Medicine, Jiangsu University, Zhenjiang, China.
Xiujuan FanInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yuepeng ZhouInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Dongfang DaiInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Deqiang WangInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Deyu ChenInstitute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Sheng XiaDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID 0000-0002-0663-6988
Minghui ZhangSchool of Medicine, Tsinghua University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ErbB ReceptorsLung NeoplasmsMutationNatural Killer T-CellsAdultAgedCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesCombined Modality TherapyFemaleGefitinibHumansImmunotherapyMaleMiddle AgedNeoplasm StagingEGFR protein, humanErbB ReceptorsGefitinibProtein Kinase InhibitorsCD8EGFRgefitinibimmunotherapyNKT cellNSCLC

Identifiers

PMID39166278
PMCPMC11339933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.